Sanofi-Aventis (SNY) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Sanofi-Aventis (SNY)

43.36

-0.43 (0.98%)

as of Jul 23, 2026, 8:00:00 pm Market Open.

91 watching

Investor Insights

Jul 23, 2026, 12:00 am

This summary was created by AI, based on 1 opinions in the last 12 months.

Sanofi-Aventis (SNY) has received mixed reviews from experts, with one indicating it as a top pick as of June 5, 2025, while also noting a significant decline of 6.5%. The stock recently triggered its stop-loss at $47, which suggests caution for investors as the market conditions may not be favorable for further investment at this moment. The recommendation from the Stockchase Research Editor, Michael O'Reilly, emphasizes the importance of discipline in trading, suggesting that investors should consider covering their positions. This indicates that while the stock may have been a good pick previously, current market trends are not aligning positively for this investment. Overall, the sentiment appears to be leaning towards a defensive strategy as the situation evolves.

Consensus

Sell

Valuation

Overvalued

Similar

Roche, ROG

DON'T BUY

Done well recently as part of the vaccine trade. No real revenue growth over the last 5 years. Stagnant profits. Decent dividend. See his Top Picks today for exposure to healthcare.

DON'T BUY

They are waiting for approval for their vaccine against COVID in Japan. They are pretty much an oncology firm. You have to compare against other companies in the sector. This one does fine with a PE of 8.8 times and the payout ratio is quite low. The dividends and cash flow are not growing, however. They have to come out with a blockbuster product. See his top picks today for a preferable.

BUY

A very good company. Pays a 3.5% dividend yield. Historically, he expected more from their Covid vaccine, though.

PAST TOP PICK

(A Top Pick Mar 12/20, Up 36%) The same idea as GSK. Hasn't done a whole lot. They are actually working on a Covid vaccine. In the meantime, non-covid visits have been decreased so there has been a hit on prescriptions. Once it comes back, they should do fine.

COMMENT

In late-2019, a new CEO arrive to turn things around by spinning off the so-so consumer business and making small acquisitions. However, Covid hit them hard, and their vaccine development has disappointed. Reported a solid quarter this morning with a slight revenue miss, but strong earnings beat and bullish guidance for 2021. The stock rose 2%. Will it get its groove back?

BUY

A French pharma. He bought this not for its vaccine, but because it's a well-run pharma, not facing patent expirations, and has good growth and returns in the future. He doesn't know where their vaccine stands now, but if it works, it will certainly boost the stock. Has strong dividend and earnings growth.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Stockchase Research Editor: Michael O'Reilly SNY is a French biotech that produces a wide range of vaccines and pharmaceuticals by prescription. It produces a drug for children aged 6-11 years with atopic dermatitis. Sales of the drug jumped almost 70% last year and it is on pace to earn the company $12 billion in revenues in the near future. The company is also vying to be another COVID-19 vaccine producer as it plans to introduce Phase 3 trials on a prospective candidate this month. It pays an excellent dividend, backed by a 38% payout ratio. We would buy SNY with a stop-loss at $45, looking towards an initial target of $61 -- 20% upside. Yield 3.36% (Analysts’ price target is $61.38)

TOP PICK

It is not economically sensitive even though the stock is getting hit. It is one of the biggest vaccine manufacturers in the world. They are working on a CoVid19 vaccine and they own an arthritis drug that could be a possible drug for treatment of CoVid19. (Analysts’ price target is $56.93)

TOP PICK

A French drug company that is starting to run. Th patent cliff has occurred and they have been busy bringing in new products. They also have a very profitable consumer health business. Yield 3.44% (Analysts’ price target is $54.17)

TOP PICK

A great global business. A bit boring, but not worries about a big drug coming off patent. He expects healthy dividend growth over time. (Analysts’ price target is $52.00)

PAST TOP PICK

(A Top Pick Aug 14/18, Up 7%) One of the largest pharma companies in the world. Their major products are looking good and their product pipeline has lots of opportunities.

WEAK BUY

It hasn't done much lately. Boring. Little volatility. They have a great vaccine business and some exposure to Africa. Slow growth, but you get a great dividend. A conservative play.

PAST TOP PICK

(A Top Pick Jul 04/18, Up 13%) One of three drug stocks he still owns. He likes the product selection and bought into it when they had a few key drugs that were coming off patent and the stock price had dropped. He has confidence they will continue to add new profitable drugs.

HOLD

A French multi-national pharma that he owns. They get research going and buy smaller companies. They only need one or two promising drugs to make out well. A good long term hold.

HOLD

Large cap out of France. Diversified. Likes the biologic focus. Bring more of an emerging market focus. Won't shoot the lights out, but likes the stable dividend and the 7.5% EPS growth. Not paying a lot for it.

Showing 16 to 30 of 48 entries

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Greg Newman

Scotia Wealth Management

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Jim Cramer - Mad Money

CNBC

John Stephenson

Stephenson & Company Capital Management

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Sanofi-Aventis (SNY)